title: Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
abstract: OBJECTIVE
  The present study analyzed the polymorphisms of apoptosis-related genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer.
  
  
  METHODS
  A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 15 apoptosis-related genes (TP53, BCL2L, TNFRSF10B, AKT1, PTGS2/COX2, BID, RIPK1, FAS, FASL, caspase 3, and caspase 6-10) were determined using a PCR-RFLP assay.
  
  
  RESULTS
  No significant association between the polymorphisms and the response was found for any of the genes analyzed. However, the T/T genotype of PTGS2 8473T>C (rs5275) was significantly correlated with a better progression-free survival (PFS) and overall survival (OS) when compared to the combined T/C and C/C genotype (Hazard ratio [HR] = 0.47; P value = 0.046 and HR = 0.16; P = 0.013, respectively) in a multivariate analysis adjusted for age, sex, performance status, disease status and curative resection. No association was noted between the other polymorphisms and survival.
  
  
  CONCLUSIONS
  The PTGS2 8473T>C polymorphism was found to be correlated with PFS and OS in patients with advanced colorectal cancer treated with XELOX chemotherapy.
authors.affiliation: Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Jung-Gu, Daegu, Korea. jkk21c@mail.knu.ac.kr
authors.forename: Jong Gwang
authors.initials: JG
authors.lastname: Kim
authors.forename: Yee Soo
authors.initials: YS
authors.lastname: Chae
authors.forename: Sang Kyun
authors.initials: SK
authors.lastname: Sohn
authors.forename: Joon Ho
authors.initials: JH
authors.lastname: Moon
authors.forename: Hun Mo
authors.initials: HM
authors.lastname: Ryoo
authors.forename: Sung Hwa
authors.initials: SH
authors.lastname: Bae
authors.forename: Yoonseop
authors.initials: Y
authors.lastname: Kum
authors.forename: Seong Woo
authors.initials: SW
authors.lastname: Jeon
authors.forename: Kyoung-Hoon
authors.initials: KH
authors.lastname: Lim
authors.forename: Byung-Mo
authors.initials: BM
authors.lastname: Kang
authors.forename: In-Ja
authors.initials: IJ
authors.lastname: Park
authors.forename: Gyu Seog
authors.initials: GS
authors.lastname: Choi
authors.forename: Soo-Han
authors.initials: SH
authors.lastname: Jun
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D051546:Cyclooxygenase 2 / Q000235:genetics*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D041722:Genes, Transgenic, Suicide / Q000235:genetics; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011110:Polymorphism, Genetic / Q000235:genetics; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D051546:Cyclooxygenase 2; D005472:Fluorouracil